cycle. In conclusion, we show that PIM2 kinase inhibition is a rational approach in DLBCL treatment, identify appropriate biomarkers for pharmacodynamic studies, and provide a new marker for patient stratification.
Western blot
For western blot, proteins were extracted using RIPA buffer (Sigma-Aldrich Inc., St Louis, MO) containing protease inhibitor (Roche, Basel, Switzerland) . 40 μ g of protein were resolved by SDS-PAGE on a 12-15% gel and transferred to nitrocellulose membranes (Millipore, Billerica, MA). Membranes were blocked in 5% bovine serum albumin and incubated with primary antibodies. They were then incubated with goat anti-rabbit IgG, goat anti-mouse IgG or donkey anti-goat IgG secondary antibodies (Alexa 680 nm or Alexa 800 nm, Rockland, Gilbertsville, PA)
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Primary antibodies were purchased as follows: BAD (#9292), pBAD(Ser112) (#9291), AKT (#9272), PIM2 (D1D2) (#4730), 4E-BP1 (53H11) (#9644), p4E-BP1(Thr37/46) (#2855), p4E-BP1 (S65) (#9456) from Cell Signaling Technology, Inc., Danvers, MA; PIM1 (12H8) (sc-13513) from Santa Cruz Biotechnology, Inc., Santa Cruz, CA; pAKT(Ser473) from BD, Franklin Lakes, NJ; and α -tubulin (T-6074) from Sigma-Aldrich.
Oligonucleotide microarray analysis of gene expression
Gene-expression profiling was conducted in a series of 114 B-cell non-Hodgkin lymphoma patients (DLBCL, FL, MALT, MCL, CLL and NMZL). Total RNA was extracted from frozen tumor samples using the Trizol reagent (Invitrogen, Carlsbad, CA, USA), and purified and treated with RNase-free DNase I using the RNeasy kit (Qiagen Inc., Valencia, CA). RNA for geneexpression profiling was hybridized on a Whole Human Genome Agilent 4X44K Oligonucleotide Microarray (Agilent Technologies, Inc., Santa Clara, CA). Total RNA extraction and purification, amplification, labeling, hybridization to Agilent 44K Human Whole Genome microarrays and scanning of output image files were performed according to the manufacturer's instructions.
Data were normalized using the Feature Extraction (v.9.0) program. All microarray data are available at the Gene Expression Omnibus (GEO) under accession number GSE32018.
Gene set enrichment analysis
The Gene Set Enrichment Analysis (GSEA) tool (http://www.broad.mit.edu/gsea/) was used to explore functional gene sets, allowing the interpretation of complete gene-expression data in relation to PIM1, PIM2 and PIM3 expression. The gene sets co-regulated with PIM1, PIM2 and PIM3 expression were identified using Pearson correlation, with a minimum of 10 and a maximum of 500 genes per gene set being required to qualify them for further analysis. The selected gene sets were compared with the Lymphoma-Enriched BioCarta (LEB) database, which contains selected gene sets from the BioCarta pathways (http://www.biocarta.com/) and previously published B-cell NHL gene signatures 35 . Gene sets with an FDR less than 0.25 were considered significant. 
Real-time quantitative PCR
RNA from frozen tissues was extracted according to standard procedures. Expression of mRNA for PIM2 was measured with the use of TaqMan Gene Expression Assays-on-Demand (Applied Biosystems, Foster City, CA). GUSB was used as an endogenous gene. Quantitative reverse transcriptase PCR (RT-PCR) reactions were performed in triplicate with the ABI Prism 7900
Sequence Detector System (Applied Biosystems). Ct values were exported using SDS software (SDS 2.3), and Δ CT and RQ (2-ΔΔCT) were calculated using Stratagene Universal Human Reference RNA (Agilent Technologies, Inc., Santa Clara, CA) as the calibrator.
Tissue microarrays and immunostaining techniques
Immunohistochemical (IHC) expression of PIM2 was assessed using tissue microarrays (TMAs) for an additional subset of 176 DLBCL tumoral samples. Histological criteria used for their diagnosis and classification were those of the World Health Organization Classification 1 . All cases positively stained for CD20. GC and ABC were subclassified using the algorithm described by Choi and coworkers 5 . Immunohistochemistry was performed on these TMA sections using PIM2 mouse monoclonal antibody (clone ANI165B) (see Materials and Methods in Supplementary Figure 1) . To ensure the reproducibility of this method, we employed straightforward, clear-cut criteria, and cases were scored as positive (1) or negative (0) for PIM2 antibody when distinct, strong nuclear or cytoplasmic expression was present in most of the neoplastic cells. Whole-tissue sections from reactive lymph node, thymus, spleen, and tonsillectomy specimens were used for the analysis of benign lymphoid subpopulations.
Statistics
The Kaplan-Meier method was used to estimate the distributions of overall survival (OS) and progression-free survival (PFS) 36 . OS was considered as the time from diagnosis to the date of death from any cause or last contact. PFS was calculated from the time of diagnosis to the date of relapse, death or loss. OS and PFS were calculated according to the definition of Cheson et . SPSS version 17.0 (SPSS, Chicago, IL) was used for these analyses.
RESULTS

PIM genes are differentially expressed in NHLs
We analyzed the gene-expression profiling data in this series of 114 NHL patients. The data revealed an increased expression of some PIM family members in subsets of MCL, DLBLC, FL, MZL-MALT, CLL and NMZL cases, compared with reactive tonsils and lymph nodes (Figure 1 ).
Thus, 29% (5/17) of CLL patients, 32% (7/ 22) of DLBCL patients and 29% (7/24) of MCL patients had a high level of PIM1 expression (> 2-fold), whereas the expression of PIM2 was increased (> 2-fold) in 76% (13/17) of CLL, 45% (10/22) of DLBCL, 30% (7/23) of FL, 80%
(12/15) of MZL-MALT, 25% (6/24) of MCL and 77% (10/13) of NMZL. No differences (> 2-fold)
were observed in PIM3 expression.
Pathways co-regulated with PIM kinases across NHL types
To identify enriched genes sets we conducted gene-set enrichment analysis in the complete series of patients (including DLBCL, FL, MALT, MCL, CLL and NMZL) and controls (lymph nodes and reactive tonsils). We used the Pearson correlation coefficient to identify genes coregulated with the expression of PIM1, PIM2 or PIM3 genes (Supplementary Table 1 Figure 2A , B). In contrast, 23% (41/176) of DLBCL cases exhibited strong nuclear and/or cytoplasmic positivity for PIM2 ( Figure 2C , D), although this was more frequent in the ABC-DLBCL subtype (28/102, 27%) than in the GC subtype (13/74, 18%).
In addition, the expression of PIM2 kinase was investigated in the DLBCL cell lines (HBL-1, HLY-1, MD-901, OCILY-10, OCILY-3, RIVA, U2932, OCILY-19, SUDHL-4 and SUDHL-6) using western blot. Cell lines characteristic of the germinal center DLBCL subtype (OCILY-19, SUDHL-4 and SUDHL-6) expressed low levels of PIM2 protein, while ABC-DLBCL cell lines (HBL-1, HLY-1, MD-901, OCILY-10, OCILY-3, RIVA and U2932) showed high levels of expression of PIM2 (p = 0.017; Figure 2E ). The expression of PIM2 kinase was also investigated by qRT-PCR, showing a relatively good correlation between mRNA and protein expression (p < 0.001; data not shown). 
Biomarkers of PIM inhibition: AKT, BAD, 4E-BP1
Several substrates of PIM kinase activity have been described in the literature 3, 10, 11, 12, 13, 14, 16, 17 .
PIM kinases bind to, phosphorylate and inactivate BAD, both in vitro and in vivo, on Ser112, a gatekeeper residue for its activation and apoptotic resistance 10, 11 . Treatment of DLBCL cells with 10 μM ETP-39010 for 4 h resulted in a maximum decrease of 20% in BAD-phosphorylation at Ser112, while the total amount of BAD remained unchanged ( Figure 4C ). As the reduction in p-BAD levels was less than expected after PIM inhibition, additional PIM substrates were shows that the phosphorylation of AKT at Ser473 was almost completely inhibited relative to the total amount of AKT protein in RIVA and U2932 cell lines, whereas a reduction of about 40%
was observed in the remaining three cell lines ( Figure 4A ). These data suggest that ETP-39010's mechanism of action involves the regulation of AKT phosphorylation.
Interestingly, recent studies in T-cell lymphomas suggest a role for PIM kinases in modulating the mTORC1 pathway through the phosphorylation of 4E-BP1 Figure 4B ).
PIM2 genetic inhibition
With the intention of refining the analysis and distinguishing whether previously described results were a consequence of inhibiting the highly expressed PIM2 or if a simultaneous inhibition of all three PIM kinases was required, we carried out an independent genetic inhibition of PIM2. For this purpose we used two independent sets of small interference RNA against PIM2 in two ABC-DLBCL cell lines: RIVA and U2932. Western blot analysis of cell lysates demonstrated a 70% downregulation of PIM2 protein levels in the U2932 cell line, whereas a reduction of 40% was observed in the RIVA cell line ( Figure 5A ). In parallel with the inhibition of PIM2 kinase, a decrease in phosphorylation of 4E-BP1 was observed at two different residues (Ser65 and Thr37/46) in both U2932 and RIVA cell lines ( Figure 5A ). These results indicate that PIM2 kinase has an active role in the regulation of the mTORC1 pathway. Its role in the activity of mTORC2 pathway was also examined, by measuring changes in AKT phosphorylation at Ser473. Only a slight inhibition of AKT phosphorylation was observed after PIM2 inhibition, indicating that PIM2 has not a main role in the regulation of mTORC2 pathway in the studied cell lines.
Apoptosis and cell-cycle analysis of DLBCL cell lines was performed 24, 48 and 72 h after microporation. In contrast with findings from ETP-39010 treatment, no effect on apoptosis was detected in RIVA or U2932 cells after PIM2 inhibition. As the ETP-39010 compound is a pan-PIM kinase inhibitor, we decided to check whether a simultaneous inhibition of all three kinases was required. Our results revealed 30% apoptosis in both U2932 and RIVA cell lines 24 and 48 h after simultaneous inhibition of all three kinases ( Figure 5B ), our results being consistent with those from pharmacological inhibition.
Clinical correlation
There are several lines of evidence associating PIM expression with poor prognosis in most hematopoietic malignancies 3, 21 . In particular, PIM1 expression has been described as a predictor of poor outcome in mantle cell lymphoma 21 . To establish whether differences observed in the intensity of the expression of PIM2 protein were associated with clinical outcome, we used the Kaplan-Meier method to compare high with low or undetectable PIM2 IHC expression in the DLBCL series. Patients who were positive for PIM2 expression appeared to have a shorter OS (p = 0.001) ( Figure 6A ). When DLBCL cases were divided into GC and ABC phenotypes, the difference in survival probability was shown to be restricted to those of the ABC-DLBCL subtype ( Figure 6B ).
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In fact, pathways associated with the PIM3 signature differ completely from those associated with PIM1 and PIM2, suggesting dissimilar roles, at least in B-cell lymphoma.
The expression of PIM genes is induced by multiple cytokines through the activation of JAK/STAT signaling pathways 45, 12 . Recent findings have implicated PIM1 in the regulation of SOCS-1, a negative regulator of the JAK/STAT pathway, and suggested that PIM1 can also modulate cytokine signaling pathways in addition to its role as a direct effector kinase The discovery of PIM serine/threonine kinase involvement in development and progression of several cancers has made PIM kinases the object of pharmaceutical interest 42 , and some chemical compounds or specific antibodies have already been found to have an inhibitory effect on them 29, 30, 31, 32, 33 . Given the existence of PIM1 somatic mutations in DLBCL 28 and the increased expression of PIM1 and PIM2 in the ABC-DLBCL subtype 3 , we decided to focus our studies on DLBCL cases and cells, using genetic inhibition and a novel pan-PIM kinase inhibitor The identification of molecular biomarkers characteristic of PIM activity is one of our areas of interest. Several such biomarkers have been described in the literature, including cell-cycle regulators (p21 CIP1/WAF1,12 , CdC25C 47 , C-TAK1 
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We conducted gene-set enrichment analysis in the complete series of patients (including DLBCL, FL, MALT, MCL, CLL and NMZL) and controls (lymph nodes and reactive tonsils). We used the Pearson correlation coefficient to identify pathways co-regulated with the expression of either PIM1, PIM2 or PIM3 genes. PIM2 expression was significantly associated with a larger series of significant gene sets. Western blot analysis of PIM2, p4E-BP1(Thr37/46) and p4E-BP1(Ser65), in RIVA and U2932 cell lines. Knockdown inhibition of PIM2 was achieved with two independent sets of small interference RNA: siRNA1 (L-005359-00-0005) and siRNA2 (s21751). siRNAs with sequences that do not target any gene product (scramble) were used as controls. Bands were quantified using the ImageJ program and the ratio of phosphorylated to total protein was calculated. The blot is representative of two independent experiments. B) Induction of apoptosis and cell-cycle were measured 24 h and 48h after knockdown inhibition of PIM1, PIM2 (siRNA1 and siRNA2), PIM3, or the simultaneous inhibition of all three PIM family members using either PIM2-siRNA1 or PIM2-siRNA2 (T-siRNA1 or T-siRNA2, respectively). Scrambled siRNAs were used as controls. No effects on cell cycle were observed at any time or with any siRNA combination (See Supplementary table 2 Kaplan-Meier analysis and the log-rank test gave significant results for overall survival and progression-free survival relative to the ABC-DLBCL subtype.
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